Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
HLA Laboratory, |
RCV001788481 | SCV001712126 | association | Interstitial lung disease 2 | 2021-05-04 | no assertion criteria provided | case-control | |
HLA Laboratory, |
RCV001788482 | SCV001712131 | association | Chronic obstructive pulmonary disease | 2021-05-04 | no assertion criteria provided | case-control | |
HLA Laboratory, |
RCV002472378 | SCV001749000 | uncertain significance | Combined pulmonary fibrosis-emphysema syndrome | 2021-05-04 | no assertion criteria provided | case-control | |
HLA Laboratory, |
RCV004995924 | SCV005044895 | uncertain significance | Susceptibility to severe coronavirus disease (COVID-19) | 2024-05-13 | no assertion criteria provided | research | The NC_000004.12:g.88890044G>T (rs2609255) is an intron variant in FAM13A (family with sequence similarity 13 member A), which has been associated with risk of chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis. We evaluated this variant in 923 patients with COVID-19 and we found no association with mortality or severity risk. However, in the post-COVID-19 group, we found that the T allele of rs2609255 was associated with lower diffusing capacity of the lungs for carbon monoxide in patients evaluated one year after discharge due to severe COVID-19. Due to the lack of association of the variant with the studied phenotypes, it was classified as uncertain significance. |